The importance of patient-reported outcomes in clinical trials and strategies for future optimization
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Patient-reported outcomes (PROs) can be included in clinical trials as primary or secondary endpoints and are increasingly recognized by regulators, clinicians, and patients as valuable tools to collect patient-centered data. PROs provide unique information on the impact of a medical condition and its treatment from the patient's perspective; therefore, PROs can be included in clinical trials to ensure the impact of a trial intervention is comprehensively assessed. This review first discusses examples of how PRO endpoints have added value to clinical trial interpretation. Second, it describes the problems with current practices in designing, implementing, and reporting PRO studies, and how these problems may be addressed by complying with guidance for protocol development, selecting appropriate PRO measures to match clinically motivated PRO hypotheses, minimizing the rates of avoidable missing PRO data, analyzing and interpreting PRO data, and transparently reporting PRO findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The weaRAble-PRO study administered a selection of validated PRO measures for RA in complement to bespoke digital PRO assessments—that are validated in clinical trials”
From Digital health technologies and machine learning augment patient reported outcomes to remotely characterise rheumatoid arthritis (2024) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363 · cited 2×
“It should be used in conjunction with the SPIRIT 2013 statement 32,33 when developing a research protocol for a trial with a primary or important secondary PRO endpoint.”
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251 · cited 2×
“It should be used in conjunction with the SPIRIT 2013 statement 32,33 when developing a research protocol for a trial with a primary or important secondary PRO endpoint.”
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000251 · Cited by 2,296
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580 · cited 2×
“21,22 The PRO endpoints led to regulatory approval of mitoxantrone for this indication and wide implementation in the clinic.”
InfluentialSelf-citationReporting of Patient-Reported Outcomes in Randomized Trials: The CONSORT PRO Extension
Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., & CONSORT PRO Group, F. T. (2013) · JAMA · doi:10.1001/jama.2013.879 · Cited by 1,386 · cited 2×
“This work informed the development of a CONSORT-PRO Extension (Consolidated Standards of Reporting Trials), which can be considered the minimum reporting items for PRO endpoints (primary or key secondary) in RCTs. 73 CONSORT-PRO consists of 14 items, five of which were newly developed PRO-specific reporting recommenda…”
Self-citationReducing waste from incomplete or unusable reports of biomedical research
Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., Michie, S., Moher, D., & Wager, E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62228-x · Cited by 1,319 · cited 1×
“However, the issue of non-reporting of PROs is emerging and requires attention, as it is unethical to waste the funding, resources, and patients’ efforts expended in PRO data collection.(71)”
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · cited 2×
“In oncology, for example, the American Society of Clinical Oncology (ASCO)(10) and European Society for Medical Oncology (ESMO)(11) have proposed standardized approaches to evaluate clinical trial results by using scores to evaluate the Magnitude of Clinical Benefit (ESMO MCB) or the Net Health Benefit (ASCO), which i…”
Calvert, M., Kyte, D., Mercieca-Bebber, R., Slade, A., Chan, A.-W., King, M. T., and the SPIRIT-PRO Group, Hunn, A., Bottomley, A., Regnault, A., et al. (2018) · JAMA · doi:10.1001/jama.2017.21903 · Cited by 814 · cited 5×
“A second review examined the PRO content of 26 protocols of Phase III international, ovarian cancer trials published between 2000 and 2016 against a list of PRO-specific items that would eventually inform the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)-PRO Extension.(29,30) Of the 26 tr…”
InfluentialSelf-citation
Research works printed but not linked: 2
- [15]Food and Drug Administration Ovarian Cancer Endpoints Workshop April 26, 2006, Meeting Summary 2006 Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Developmen-tResources/CancerDrugs/ucm094598.pdf accessed 09 August 2016 https://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm120657.pdf Accessed 14 August 2017.v
- [56]Mercieca-Bebber R Palmer MJ Brundage M Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review BMJ Open 2016 6 6 e010938 PMC4916640 27311907
Cited by
Items 201–300 of 660
The use of healthcare systems data for RCTs
Toader, A.-M., Gamble, C. L., Dodd, S. R., & Williamson, P. R. (2024) · Trials · doi:10.1186/s13063-023-07846-4 · Cited by 10
“There were no sub-studies looking at PRO data from HSD.”
BackgroundTherrien, F., Ward, C., Chokka, P. R., Habert, J., Ismail, Z., McIntyre, R. S., & MacKenzie, E. M. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437241233965 · Cited by 9
“6 This study is limited by its open-label nature and the lack of a comparator arm.”
BackgroundAl-Karni, M. A. T., Omar, M. T. A., Al-Dhwayan, N., Ajarim, D. S., Idreess, M. J. N., & Gwada, R. F. M. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.3.951 · Cited by 8
Kang, M., Yoo, S., Jung, Y., Lim, H., Lee, M. H., Ryu, J. K., & Lee, J. I. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16210 · Cited by 7
Trigg, A., Ayasse, N. D., & Coon, C. D. (2024) · Quality of Life Research · doi:10.1007/s11136-024-03798-7 · Cited by 9
“Clinical outcome assessments (COAs), including patient-reported outcome (PRO) measures, are an important approach to measure the possible benefits and harms of treatments in randomised controlled trials (RCTs) [ 1 ].”
Filanovsky, K., Haran, M. Z., Mirkin, V., Braester, A., Shevetz, O., Stanevsky, A., Sigler, E., Votinov, E., Zalzman-Amir, Y., Berrébi, A., et al. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.072 · Cited by 8
Nascimento, D. D. C., Neto, I. V. D. S., Saraiva, B., Lima, A. D. S., Navalta, J. W., Pereira, G. B., Willardson, J. M., Beal, F. L. R., & Prestes, J. (2020) · Blood Pressure Monitoring · doi:10.1097/mbp.0000000000000505 · Cited by 8
Ketola, H., Kask, G., Barner-Rasmussen, I., Tukiainen, E. J., BLOMQVIST, C. P., Laitinen, M., Kautiainen, H., Kiiski, J., & Repo, J. P. (2021) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2021.11.081 · Cited by 9
Fleischmann, R., Hayes, K., Ahn, S.-W., Wan, G. J., Panaccio, M. P., Karlsson, D., & Fürst, D. E. (2021) · Rheumatology and Therapy · doi:10.1007/s40744-021-00412-x · Cited by 8
“Correlating improvements in PROs with clinical outcomes provides further insights into patients’ response to therapy and its impact on improvements in fatigue, pain, and disability [16].”
BackgroundO’Quinn, S., Shih, V. H., Martin, U. J., Meyers, O. I., Crooks, P., Bailey, J. R., & Slagle, A. F. (2021) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22952 · Cited by 9
Warsame, R. M., Cook, J., Fruth, B. F., Hubbard, J. M., Croghan, K. A., Price, K. A. R., Jatoi, A., Kumar, S. K., Thompson, C. A., Buckner, J. C., et al. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.100964 · Cited by 7
Wood, K. C., Hidde, M. C., Kendig, T., & Pergolotti, M. (2022) · Breast Cancer · doi:10.1007/s12282-022-01388-4 · Cited by 8
Caffery, B. E., Petris, R., Hammitt, K. M., Montecchi-Palmer, M., Haque, S., Malkowski, J., & Barabino, S. (2022) · European Journal of Ophthalmology · doi:10.1177/11206721221125263 · Cited by 9
“patient journey, increase societal awareness to seek timely treatment, build trust within the patient community, and improve patient recruitment and participation in clinical trials and adherence to therapy.(6,7) The European Medicines Agency and U.”
BackgroundNovel Endpoints in Solid Organ Transplantation: Targeting Patient-reported Outcome Measures
Ju, A., Cazzolli, R., Howell, M., Scholes-Robertson, N. J., Wong, G., & Jauré, A. (2023) · Transplantation · doi:10.1097/tp.0000000000004537 · Cited by 10
Shih, V. H., Jison, M. L., Bark, E., Venerus, M., Meyers, O. I., & Chalmers, J. D. (2023) · ERJ Open Research · doi:10.1183/23120541.00712-2022 · Cited by 8
Golden, A. H., Gabriel, M. H., Russo, J., Price, M. A., Ruhmel, S., Nilsson, A., Delong, P. S., Jelsma, J. M., & Carty, M. K. (2023) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-023-00666-9 · Cited by 10
“Finally, published PRO data provide clinicians, patients, family members, and caregivers with valuable information regarding patients’ experiences with a disease or treatment, assisting them in treatment selection for improved patient outcomes [4].”
BackgroundBerry, L., Walter, J., Johnson, J. L., Alton, J., Powers, J., Llòria, X., Koulinska, I. N., McGee, M., & Laney, D. A. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03090-4 · Cited by 9
“Examples of PROs include disease symptoms or treatment side effects such as pain, fatigue, or anxiety; functional outcomes such as physical, sexual, social, emotional, or cognitive functioning; or multidimensional constructs such as health-related QoL or health utility [20, 21].”
BackgroundDistinct Constructs Underlie Patient‐Reported and Performance‐Rated Outcomes after Stroke
DiCarlo, J. A., Jaywant, A., Gochyyev, P., Bonkhoff, A. K., Hardstone, R., Erler, K. S., Ranford, J., Cloutier, A., Ward, N., Sloane, K. L., et al. (2024) · Annals of Neurology · doi:10.1002/ana.27129 · Cited by 7
Cocks, K., King‐Kallimanis, B. L., Sims, J., Worthy, G., Stein, J., Ayala‐Nunes, L., Achra, M., Cui, Z. L., & Payakachat, N. (2024) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-024-00824-7 · Cited by 8
Young, I. A., Dunning, J. R., Mourad, F., Escaloni, J., Bliton, P., & Fernández‐de‐las‐Peñas, C. (2025) · Physiotherapy Theory and Practice · doi:10.1080/09593985.2025.2450090 · Cited by 9
“In concert, these PROMs should give clinicians and researchers a more comprehensive understanding of the patient response (pain, function, and disability) to an intervention (Mercieca-Bebber et al., 2018).”
A mathematical model of CAR-T cell therapy in combination with chemotherapy for malignant gliomas
Sinelshchikov, D., Belmonte-Beitia, J., & Italia, M. (2025) · Chaos An Interdisciplinary Journal of Nonlinear Science · doi:10.1063/5.0260252 · Cited by 11
Angchaisuksiri, P., Mackensen, S. V., Apte, S., Benson, G. M., Eichler, H., Findley, A., Matsushita, T., Tavares, C. M. M., Ravn, M. P., Sathar, J., et al. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102705 · Cited by 7
“Patient-reported outcomes (PROs) provide added value to clinical study interpretation by providing insights into patient experience and perception of treatment [1,2].”
Midtgaard, K. S., Flugsrud, G. B., Jonsson, K. B., Snellman, G., Coucheron, M., Djuv, A., Grundel, D., Johnsen, L. G., Laudal, E., Mjaaland, K. E., et al. (2025) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.24.01461 · Cited by 7
Chyr, L., Sauers, E. G., Dy, S. M., & Waldfogel, J. M. (2022) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2022.08.008 · Cited by 9
Patient-reported outcomes validated in phase 3 clinical trials: a targeted literature review
Morga, A., Dibenedetto, S., Adiutori, R., & Su, J. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2224164 · Cited by 7
Bejer, A., Płocki, J., Probachta, M., Kotela, I., & Kotela, A. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20136316 · Cited by 7
Serrano, D., Cella, D. F., Husereau, D., King‐Kallimanis, B. L., Mendoza, T. R., Salmonson, T., Stone, A. A., Zaleta, A. K., Dhanda, D., Moshyk, A., et al. (2024) · Quality of Life Research · doi:10.1007/s11136-023-03587-8 · Cited by 8
Roncolato, F. T., King, M. T., O’Connell, R. L., Lee, Y. C., Joly, F., Hilpert, F., Lanceley, A., Yoshida, Y., Bryce, J., Donnellan, P. P., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.02.025 · Cited by 7
Self-citationHulbert‐Williams, L., Hulbert-Williams, N., Martins, A. P., Storey, L., Bradley, J., O’Sullivan, H., Fern, L. A., Lawal, M., Windsor, R. E., Gerrand, C., et al. (2024) · Cancers · doi:10.3390/cancers16061096 · Cited by 6
“…including length and perceived burden on the clinical teams [13], fear of bringing up topics of conversation that clinicians are not trained or equipped to follow through on [14], or that more generalisable measures may not be perceived as being patient-centred enough to be clinically useful [15].”
BackgroundYang, Z., Luo, N., & Hong, Y. (2024) · Health and Quality of Life Outcomes · doi:10.1186/s12955-024-02314-2 · Cited by 9
“PROMs provide unique information on the effect of the disease and treatment from the patients’ perspective, which can supplement conventional clinical measures like blood tests, functional tests, and imaging [11].”
Harris, M., Kazdin, A. E., Munthali, R. J., Vigo, D., Hwang, I. H., Sampson, N. A., Al-Hamzawi, A., Alonso, J., Andrade, L. H., Borges, G. L. G., et al. (2022) · International Journal of Mental Health Systems · doi:10.1186/s13033-022-00516-z · Cited by 7
“The patient’s perspective is increasingly seen as an important independent perspective on treatment [10, 11].”
BackgroundRutherford, C., & Boehnke, J. R. (2022) · Quality of Life Research · doi:10.1007/s11136-022-03194-z · Cited by 9
Abasıyanık, Z., Veldkamp, R., Fostier, A., Goubergen, C. V., Kalron, A., & Feys, P. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192215029 · Cited by 7
“Therefore, PROMs focusing on DT performances are essential [13].”
Lyhne, J. D., Smith, A. B., Jensen, L. H., Hansen, T. F., Frostholm, L., & Timm, S. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02236-z · Cited by 9
“Quality of life measures are necessary to include as primary or at least secondary outcomes in interventional research [4–6].”
BackgroundRegistered Reports at “Quality of Life Research”
Boehnke, J. R., & Rutherford, C. (2020) · Quality of Life Research · doi:10.1007/s11136-020-02638-8 · Cited by 8
Medical cannabis use in oncology and associated outcomes: A scoping review
Valente, A. C., Lopes, L. P. N., & Matheus, M. E. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241239006 · Cited by 7
Lacey, H., Bernard, K., Syed, L., O'Rourke, E., Calvert-Ford, Y., Bovis, J., Guryel, E., & King, I. C. C. (2024) · JPRAS Open · doi:10.1016/j.jpra.2024.08.003 · Cited by 6
Nikolovski, J., Morton, R. L., Mercieca‐Bebber, R., Armstrong, M., Hartas, G., Rossiter, B., Fagan, M., Tinsley, M., Snyder, C. F., Aiyegbusi, O. L., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-083346 · Cited by 7
Self-citationShah, D., Sparano, F., Luo, C. K., Krepper, D., Giesinger, J. M., Baldi, T., Duncan, E., Pe, M. L., Chakraborty, R., & Efficace, F. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06129-5 · Cited by 7
“Hence, direct measurement of patient-reported outcomes (PROs) in randomized controlled trials (RCTs) is critical to evaluate the impact of a new treatment on patients’ HRQoL [8, 9].”
Sand‐Svartrud, A., Kjeken, I., Skardal, R. F., Gjerset, G. M., Johnsen, T. J., Lyken, A. D., Dagfinrud, H. S., & Moe, R. H. (2024) · BMC Health Services Research · doi:10.1186/s12913-024-12103-8 · Cited by 6
van Karnebeek, C., Müller, A. R., Benkemoun, L., Boussaad, I., Cornel, M. C., IntHout, J., de Kort, M., Oliveira‐Martins, S., Prigione, A., Rigter, T., et al. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109073 · Cited by 7
Chien, S.-Y. (2025) · Digital Health · doi:10.1177/20552076251340183 · Cited by 7
“27,39,40 We aimed to enhance the app ’ s usability and acceptance in clinical settings.”
Fouad, Y., Elwakil, R., Sanai, F. M., Ojo, O. S., Awadhi, S. A., Ocama, P., Abdelkader, N. A., Al‐Busafi, S. A., Awuku, Y. A., Zaki, S., et al. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102180 · Cited by 10
Klassen, A. F., Rae, C. S., O'Malley, M., Breitkopf, T., Algu, L., Mansouri, J., Brown, C., Wáng, Y., & Lipner, S. R. (2023) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s429120 · Cited by 7
Orlando, L., Maiello, E., Orditura, M., Diana, A., Antoniol, G., Morritti, M. G., Aieta, M., Ciccarese, M., Pisconti, S., Bordonaro, R., et al. (2024) · The Breast · doi:10.1016/j.breast.2024.103725 · Cited by 6
“The inclusion of PROMS in clinical trials might enhance the understanding of treatment and disease impact on quality of life (HRQoL) [11] .”
BackgroundMethodStasi, S., Papagiannis, G. I., Triantafyllou, A. I., Papagelopoulos, P. J., & Koulouvaris, P. (2024) · Journal of Functional Morphology and Kinesiology · doi:10.3390/jfmk9030110 · Cited by 6
“…the use of self-reported outcomes like OHS can provide unique information on the impact of treatment from the patient’s perspective [40], and it is complementary to the overall assessment of patients’ recovery; this is essential in clinical research and practice involving THA patients [40].”
BackgroundImproving Transition to Adult Care for Those With Developmental Disabilities: An Unclear Path
Hart, L. C. (2020) · PEDIATRICS · doi:10.1542/peds.2020-024398 · Cited by 7
Canonica, G. W., Klimek, L., Acaster, S., Dollner, R., Kaulsay, R., Lo, S. H., Price, D. B., Scadding, G. K., Valovirta, E. J., & Zieglmayer, P. U. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1911973 · Cited by 6
Shibli, J. A., Feres, M., Figueiredo, L. C., dos Santos, N. C. C., & Retamal‐Valdes, B. (2021) · Dental Clinics of North America · doi:10.1016/j.cden.2021.06.001 · Cited by 6
Robson, S. C., McParlin, C., Mossop, H., Lie, M., Fernandez-García, C., Howel, D., Graham, R. H., Ternent, L., Steel, A. J., Goudie, N., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25630 · Cited by 12
Psychometric parameters of food allergy quality of life during an allergen immunotherapy trial
Coelho, G. L. D. H., DunnGalvin, A., Greenhawt, M., Hourihane, J. O., Fleischer, D. M., Chen, G., Shaker, M. S., Campbell, D. E., Green, T. D., & Bégin, P. (2022) · Allergy · doi:10.1111/all.15323 · Cited by 6
de la Serna, C. D. D. L. R., Kotronoulas, G., Drury, A., Oldenmenger, W. H., & Kelly, D. M. (2022) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2022.102241 · Cited by 6
Applying multidimensional computerized adaptive testing to the MSQOL-54: a simulation study
Giordano, A., Testa, S., Bassi, M., Cilia, S., Bertolotto, A., Quartuccio, M. E., Pietrolongo, E., Falautano, M., Grobberio, M., Niccolai, C., et al. (2023) · Health and Quality of Life Outcomes · doi:10.1186/s12955-023-02152-8 · Cited by 7
“Health-Related Quality of Life (HRQOL) is one of the most used outcome measures in health research, clinical trials, and post-authorization studies [2].”
Ingram, J. R., Ciaravino, V., Rolleri, R. L., Pansar, I., Dias-Barbosa, C., & Kirby, J. S. (2023) · Dermatology · doi:10.1159/000534463 · Cited by 6
“They capture unique information about the impact of HS from the patient perspective, which may not be captured using clinician-reported endpoints [3].”
BackgroundSchoenen, S., Verbeeck, J., Koletzko, L., Brambilla, I., Kuchenbuch, M., Dirani, M., Zimmermann, G., Dette, H., Hilgers, R.-D., Molenberghs, G., et al. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03103-2 · Cited by 10
Nowojewski, A., Bark, E., Shih, V. H., & Dearden, R. (2024) · Quality of Life Research · doi:10.1007/s11136-024-03644-w · Cited by 10
“PROMs provide unique insights about the treatment from patient’s perspective and enable the impact of a trial intervention to be comprehensively assessed [3].”
Time to re-think the olanzapine dose
Molassiotis, A. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30791-0 · Cited by 6
Scheepers, E. R. M., van Huis‐Tanja, L. H., Emmelot‐Vonk, M. H., & Hamaker, M. E. (2021) · Quality of Life Research · doi:10.1007/s11136-021-02791-8 · Cited by 7
“Inclusion of PROs in clinical trials could be challenging due to the uncertainty about the quality and appropriate application of existing tools for assessing PROs [24].”
BackgroundMethodKodumuri, N., Edmunds, A., Seidel, A., Fleming, P., Vezzetti, A., Mascari, R., Kothari, R., Lowe, J., & Sen, S. (2021) · European Journal of Neurology · doi:10.1111/ene.15052 · Cited by 6
“In addition, patientreported outcome measures have gained much popularity in recent times, accounting for patient satisfaction and helping to understand the true functional outcomes based on patient experience [10].”
BackgroundPayer perceptions on the use of patient-reported outcomes in oncology decision making
Oderda, G. M., Brixner, D. I., BISKUPIAK, J. E., Burgoyne, D. S., Arondekar, B. V., Deal, L. S., Quek, R. G. W., & Niyazov, A. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.21223 · Cited by 6
Rajkumar, J. R., Jetter, N., Samuels, K., & Schwartz, A. (2020) · Pediatric Dermatology · doi:10.1111/pde.14458 · Cited by 6
Ojo, A. S., Araoye, M. O., Ali, A. S., & Sarma, R. (2023) · Journal of Cancer Survivorship · doi:10.1007/s11764-023-01332-1 · Cited by 7
“For proper interpretation of HRQoL data, a PRO publication must provide a clear description of the study design, data analysis, and interpretation of HRQoL data [93].”
Harrison‐Brown, M., Scholes, C. J., Ebrahimi, M., Field, C., Cordingley, R., Kerr, D. R., Farah, S., & Kohan, L. (2019) · The Bone & Joint Journal · doi:10.1302/0301-620x.101b11.bjj-2019-0663.r1 · Cited by 6
Psychometric Validation and Meaningful Change Thresholds of the New Nasal Polyposis Symptom Diary
Shih, V. H., Slagle, A. F., Ivanescu, C., Flore, G., Meyers, O. I., Kreindler, J. L., Martin, U. J., & Werkström, V. (2023) · Annals of Otology Rhinology & Laryngology · doi:10.1177/00034894231177769 · Cited by 6
Stewart, K. D., Matza, L. S., Patel, H., & Boye, K. S. (2023) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-023-00614-7 · Cited by 5
“Patient-reported outcome (PRO) measures can provide information on the impact of disease and treatment from the patient’s perspective, and the importance of this information is becoming more commonly recognized by clinicians and regulatory agencies [18].”
BackgroundCiucă, A., Banka, S., Clancy, T., Jones, S. A., Kirkham, J. J., Newman, W. G., Payne, K., & Moldovan, R. (2024) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2024.111617 · Cited by 7
Schuldesz, A. C., Tudor, R., Cornea, A., Geni, D. N., Lata, I., & Simu, M. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020553 · Cited by 6
Eroğlu, Z. T., Kalender, M. E., Yarkaç, F. U., Babayiğit, O., & Şen, D. Ö. (2025) · BMC Oral Health · doi:10.1186/s12903-025-05702-2 · Cited by 5
“These tools are essential for evaluating the quality of care and can offer significant insights into improving patient-centered outcomes [16, 17].”
Relationship Between Parental Distress and Proxy Symptom Reports in Pediatric Palliative Care
Hill, D. L., Nye, R. T., Boyden, J. Y., Johnston, E. E., Hinds, P. S., Friebert, S. E., Bogetz, J. F., Kang, T. I., Hall, M., Wolfe, J., et al. (2025) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2025.03.007 · Cited by 5
Heravi, A. T., Gryaznov, D., Busse, J. W., Schönenberger, C., von Niederhäusern, B., Hausheer, L., Covino, M., Schwenke, J. M., Epp, S., Griessbach, A., et al. (2025) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2025.111822 · Cited by 6
Krol, M., Maher, J., Halmos, T., Reaney, M. D., Shana'a, A., Arnould, B., Allen, V. D., & Coulouvrat, C. (2025) · Value in Health · doi:10.1016/j.jval.2025.05.002 · Cited by 5
Khan, A., Nguyen, T., Dunford, B., Khan, T., Khalid, M., Hillman, C., Shepard, S., Kee, M. D., Roberts, W., Terrell, A., et al. (2025) · Pain and Therapy · doi:10.1007/s40122-025-00766-y · Cited by 4
“Recent efforts have been made to increase the applicability of PROs within RCTs [2], thus, their transparency and adherence to reporting guidelines is essential.”
Oldenburger, E., Jomy, J., Navarro-Domenech, I., Lee, S. F., van der Velden, J. M., Wong, H. C. Y., Spalek, M. J., Marta, G. N., Hoskin, P., van der Linden, Y. M., et al. (2025) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2025.111300 · Cited by 5
Peris, C. C., Cosgrove, M. M., Chrismer, I. C., Razaqyar, M. S., Elliott, J. S., Kuo, A., Emile-Backer, M., & Meilleur, K. G. (2020) · Patient · doi:10.1007/s40271-020-00418-7 · Cited by 4
Gutiérrez, R. D. S., & Castro, R. P. (2022) · Current Allergy and Asthma Reports · doi:10.1007/s11882-022-01041-2 · Cited by 6
“These outcomes are becoming increasingly important in clinical research [36] to the extent that nowadays many studies include validated PRO questionnaires among their study variables [35].”
BackgroundPlotsker, E. L., Stern, C. S., Graziano, F. D., Rubenstein, R. N., Vingan, P. S., Haglich, K. A., Monge, J. J. L., Disa, J. J., Mehrara, B. J., Dayan, J. H., et al. (2023) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000010957 · Cited by 5
“25 For reconstructive and aesthetic breast surgery, PROs are commonly measured with the BREAST-Q, a validated survey that has been in use since 2009.”
MethodUlloa, J. H., Lurie, F., Santiago, F. R., Gianesini, S., REINA, L., Wang, J., Jindal, R., Taha, W., Bokuchava, M., & Mansilha, A. (2023) · International Angiology · doi:10.23736/s0392-9590.23.05108-8 · Cited by 5
Raez, L. E., Kang, H., Ohe, Y., Khanal, M., Han, Y., Szymczak, S., Barker, S. S., & Gilligan, A. M. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103444 · Cited by 6
Comparison of two popular transducers to measure sit-to-stand power in older adults
Balachandran, A. T., Orange, S. T., Wang, Y., Lustin, R., Vega, A., & Quiles, N. N. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308808 · Cited by 6
What Do Patients Prefer in Periodontal and Implant Therapy? A Scoping Review
Gomulinski, S., Gandillot, V., Valet, F., Agossa, K., Huck, O., Kerner, S. P., Bouchard, P., & Carra, M. C. (2025) · Journal of Periodontal Research · doi:10.1111/jre.13412 · Cited by 5
Varian, F., Burney, R., Pearson, C., Goh, Z. M., Newman, J. V., Rawlings, G. H., Zafar, H., Kiely, D. G., Thompson, A. A. R., Condliffe, R. A., et al. (2025) · European Respiratory Review · doi:10.1183/16000617.0006-2025 · Cited by 8
Lohrer, H. (2020) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-01856-7 · Cited by 5
“Since its development, it was cross-culturally translated and adapted to all major languages and is globally accepted [25,36].”
BackgroundAngst, F., Giger, R. D., Lehmann, S., Sándor, P. S., Teuchmann, P., & Csordás, A. (2022) · Health and Quality of Life Outcomes · doi:10.1186/s12955-022-01994-y · Cited by 9
“Patientreported outcomes, such as health-related quality of life (HRQL), are crucial for obtaining the patient’s perspective on the effectiveness of medical or lifestyle interventions [7].”
BackgroundComplications of Total Hip Arthroplasty
Tokgöz, E. (2022) · Springer eBooks · doi:10.1007/978-3-031-08927-5_5 · Cited by 6
Batioja, K., Peña, A. M., Smith, C., Minley, K., Wise, A., Shepard, S., Heigle, B., Ottwell, R., Hartwell, M. L., & Vassar, M. B. (2022) · Women s Health Issues · doi:10.1016/j.whi.2022.10.004 · Cited by 5
Zheng, Z., Bird, S. R., Layton, J., Hyde, A. J., Moreland, A., Wan, D. W. L., & Stupans, I. (2022) · Disability and Rehabilitation · doi:10.1080/09638288.2022.2153935 · Cited by 7
“Firstly, outcome data in clinical trials that are meaningful and relevant to clinical decision making are often lacking or not utilised in practice [13–15].”
MethodAnkle fractures: High implant cost is not associated with better patient reported outcomes
Kibble, K., Cunningham, B. P., Rivard, R. L., Vang, S. X., & Nguyen, M. P. (2023) · Injury · doi:10.1016/j.injury.2023.110963 · Cited by 7
Zhang, X., & Krabbe, P. F. M. (2023) · BMC Medical Research Methodology · doi:10.1186/s12874-023-02119-9 · Cited by 5
“Such values can be meaningful in many research situations, such as monitoring patients’ health, assessing healthcare interventions, conducting cost-effectiveness analysis, and comparing health status across different populations [1, 11–13].”
BackgroundLiu, D. T., Mueller, C. A., & Sedaghat, A. R. (2024) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.1208 · Cited by 6
“1,2 Although there is an expanding prominence and growing use of PROs in clinical practice globally, there is evidence of performance-related issues during the development of many measurement tools.”
BackgroundNasrallah, C., Wilson, C., Hamblin, A., Hariz, C., Young, C., Li, J., Yazdany, J., & Schmajuk, G. (2024) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-024-02696-9 · Cited by 5
“In line with previous studies, we found that inconsistencies in guidance on administering RA outcome questionnaires [38] and inadequate explanations about the importance of reporting these measures may reduce their perceived usefulness, hinder patient acceptance and engagement and lead to lower PRO…”
ResultRawlings, A. M., Chuang, R., Schmahmann, J. D., Perlman, S., Rosenthal, L. S., Safarpour, D., Casey, H. L., Horak, F. B., & Gomez, C. M. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.14323 · Cited by 5
“5 Patient-reported outcomes are increasingly viewed as valuable tools to capture the patient experience 27 and their use in clinical trials has increased over time.”
Prakasam, D., Wong, A. L., Smithburger, P. L., Buckley, M. S., & Kane‐Gill, S. L. (2020) · Journal of Patient Safety · doi:10.1097/pts.0000000000000734 · Cited by 5
“Patient reports such as pain measurements and diary reporting are being used as safety end points in clinical studies representing their meaningful utility.(6,7) Patient-reported outcomes are very useful as a safety indicator, and this is applicable to ADR reporting as well.”
MethodKoopman, M., Pinto, C., Bodoky, G., García‐Carbonero, R., Marti, F. M., & Bachet, J. (2022) · Future Oncology · doi:10.2217/fon-2021-1333 · Cited by 5
Fu, J. B., Stout, N. L., & Egleston, B. L. (2022) · Cancer · doi:10.1002/cncr.34373 · Cited by 5
“The variability of tools used across trials has historically inhibited betweentrial comparisons.(12) This tool, as a part of the PatientReported Outcomes Measurement Information System toolkit, could greatly improve consistency in research measures and in the reporting of function.”
MethodWee, S. N., Liman, C., Waters, H. C., Houle, C. R., Rentería, M. E., Mukherjee, S. S., Surendran, S., Marcovici, J., Brubaker, M., Meehan, S. R., et al. (2023) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s395255 · Cited by 6
“While many clinical trials on adjunctive antipsychotics and ADTs are evaluated using clinician-rated depressive symptom scales,(6,17) there is an increasing drive towards patient-reported outcomes (PROs) in clinical research, which may capture meaningful information such as quality of life.(18,19) From a patient’s per…”
BackgroundSaleh, R., Meti, N., Ribnikar, D., Goldvaser, H., Ocaña, A., Templeton, A. J., Šeruga, B., & Amir, E. (2020) · Cancer Medicine · doi:10.1002/cam4.3390 · Cited by 6
Husain, N., Ansari, Z., Shamim, M. A., Zahiri, Z., Singh, M. B., Kabir, R., Samajdar, S. S., Dhodi, D., Padhi, B. K., Kazmi, A. Z., et al. (2025) · BMJ Open Quality · doi:10.1136/bmjoq-2024-003209 · Cited by 9
Shah, D., Sparano, F., Shah, V., Krepper, D., Baldi, T., Chakraborty, R., & Efficace, F. (2025) · European Journal Of Haematology · doi:10.1111/ejh.70002 · Cited by 6
“For future guidance, increased adherence to international PRO guidelines [47] such as SPIRIT-PRO Extension [14, 22] is essential for stan-dardizing PRO protocol content and enhancing clinical interpre-tative value [12, 24].”
Jayasinghe, R. T., Ahern, S., Maharaj, A. D., Romero, L., & Ruseckaite, R. (2026) · Public Health · doi:10.1016/j.puhe.2026.106138 · Cited by 4
Novello, S., Spigel, D., Fang, J., Chen, Y., Zenke, Y., Lee, K. H., Navarro, A., Buchmeier, E. L., Jp, C., Shiraishi, Y., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103564 · Cited by 8
Metadata
- Authors
- Mercieca-Bebber, R., King, M. T., Calvert, M. J., Stockler, M. R., & Friedlander, M.
- Affiliations
- The University of Sydney (AU)
- National Institute for Health and Care Research (GB)
- Corresponding author
- Friedlander, Michael
- Venue
- Patient Related Outcome Measures
- Publisher
- Informa UK Limited
- Published
- 2018-11
- Volume
- Volume 9
- Pages
- 353-367
- ISSN
- 1179-271X (ISSN-L)
- PMC
- PMC6219423
- OpenAlex
- W2899320385
- Cited by
- 659
- References
- 73
- Citations by year
- 2026: 77 · 2025: 129 · 2024: 138 · 2023: 88 · 2022: 85 · 2021: 75 · 2020: 54 · 2019: 12
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Related Outcome Measures (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- University Hospitals Birmingham NHS Foundation Trust
- Australian Government
- National Institute for Health and Care Research
- University of Birmingham
- Cancer Australia
- Surgical Reconstruction and Microbiology Research Centre
- National Health and Medical Research Council
- Birmingham Biomedical Research Centre
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- patient-reported outcomes, clinical trial endpoints, missing data, protocol design, patient-centered outcomes, regulatory guidelines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.